ITGAX and atherosclerosis: Although even incomplete depletion in CD11c-DTR mice (with 70–80% efficacy) was reported to alter the balance of the immune response [32], and decrease inflammatory cytokine production in atherosclerosis [33] by others, we could not confirm these findings.